PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, ...